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Abstract: The exploration of quantitative variation in complex traits such as gene expression and drug response in human 
populations has become one of the major priorities for medical genetics. The International HapMap Project provides a key 
resource of genotypic data on human lymphoblastoid cell lines derived from four major world populations of European, 
African, Chinese and Japanese ancestry for researchers to associate with various phenotypic data to ﬁ  nd genes affecting 
health, disease and response to drugs. Recent progress in dissecting genetic contribution to natural variation in gene expres-
sion within and among human populations and variation in drug response are two examples in which researchers have 
utilized the HapMap resource. The HapMap Project provides new insights into the human genome and has applicability to 
pharmacogenomics studies leading to personalized medicine.
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Introduction
Phenotypic variation provides the raw materials for evolution by natural selection. Genetic variation together 
with interaction with non-genetic factors is the underlying driving force of the phenotypic changes (Nei, 
2007). In the past several years, genetic studies of gene expression have treated transcript abundance itself 
as a quantitative trait and have mapped it to human genome polymorphisms such as expression quantitative 
trait loci (eQTLs) (Pastinen, Ge et al. 2006). Unlike rare or Mendelian disease, common diseases such as 
diabetes, cancer, depression and heart disease as well as individual responses to drug treatments have been 
shown to be caused by different genes or their combination with environmental factors. Various studies 
suggest that common DNA sequence variants in genes, especially single nucleotide polymorphisms (SNPs) 
are responsible for many of these examples of variation in development of diseases, responses to pathogens, 
chemicals and drugs (Erichsen and Chanock, 2004; Bondy, 2007; Giacomini, Brett et al. 2007; Owen and 
McCarthy, 2007; Rabik and Dolan, 2007). The goal of the International HapMap Project (International 
HapMap Consortium 2003) is to develop a haplotype map of the human genome, the HapMap, to describe 
the common patterns of human DNA sequence variation. The HapMap is expected to be a key resource for 
researchers to ﬁ  nd genes affecting health, disease and response to drugs and environmental factors.
The exploration of quantitative variation in human populations has become one of the major priorities 
for medical genetics. The successful identiﬁ  cation of variants that contribute to complex traits such as 
gene expression and drug response is highly dependent on reliable assays and genetic maps. In this review, 
we brieﬂ  y introduce the publicly available HapMap resource followed by a discussion of the recent progress 
in two areas signiﬁ  cantly beneﬁ  ted from the HapMap resource: gene expression variation studies and 
pharmacogenomic studies. This resource is providing new insights into the human genome and cellular 
make-up and its impact on our understanding of the molecular basis of variable response to drugs and 
regulation of gene expression. We also discuss the advantages and limitations of the HapMap resource.
Publicly Available HapMap Resource
Four populations were selected for inclusion in the International HapMap Project (International 
HapMap Consortium 2003; International HapMap Consortium 2004; International HapMap 16
Zhang et al
Bioinformatics and Biology Insights 2008:2 
Consortium 2005; Frazer, Ballinger et al. 2007): 
30 trios from Ibadan, Nigeria (YRI), 30 trios of 
U.S. residents of northern and western European 
ancestry (CEU), 45 unrelated individuals from 
Tokyo, Japan (JPT) and 45 unrelated Han Chinese 
individuals from Beijing, China (CHB) (Fig. 1). 
Epstein Barr virus (EBV)-transformed 
lymphoblastoid cell lines (LCLs) were derived 
from these individuals. Table 1 lists the datasets 
that have been made public on these populations 
by the HapMap Project and other laboratories. 
They can be grouped in three major catogories: 
(1) genotypic data, (2) gene expression data and 
(3) other phenotypic data.
Genotypic data on the HapMap cell 
lines
The HapMap web site (Thorisson, Smith et al. 
2005) is the primary portal to genotypic data 
produced as part of the International HapMap 
Project (Table 1). More than 4 million SNPs (with 
a minor allele frequency 5%) were genotyped in 
270 LCLs from the four populations. Available 
data also include assay design information, allele 
frequency information, raw genotypes, and analytic 
results including pairwise linkage disequilibrium 
(LD) between SNPs and phased haplotypes. There 
are also public datasets for copy number variation 
(CNV), a structural genetic variation different from 
SNPs. The Database for Genomic Variants (Iafrate, 
Feuk et al. 2004; Redon, Ishikawa et al. 2006) 
contains the CNV data on 55 unrelated CEU 
samples using array-based comparative genomic 
hybridization (Albertson and Pinkel, 2003). More 
comprehensive CNV data on 270 HapMap cell 
lines have recently been made public by Stranger 
et al. (Stranger, Forrest et al. 2007).
Gene expression data on the HapMap 
cell lines
Gene expression data using different microarray 
platforms have been made public through 
Gene Expression Omnibus (GEO) for the four 
populations in the HapMap Project (Table 1). 
Although a comprehensive comparison of these 
particular expression datasets has not been 
reported (a potential topic for researchers using 
these datasets), performance across microarray 
platforms (e.g. Affymetrix, Illumina, GE Healthcare 
and Agilent) has been shown to be generally 
reliable versus other quantitative gene expression 
technologies such as TaqMan assays (Canales, 
Luo et al. 2006). One potential problem with the 
use of expression microarrays is that oligonucleotide 
hybridization could be affected by polymorphisms 
located within probes (Gilad, Rifkin et al. 2005). 
It has been shown that sequence polymorphisms 
can result in many false-positives when testing for 
cis eQTLs (Alberts, Terpstra et al. 2007). A recent 
version of expression dataset using the Affymetrix 
GeneChip
® Human Exon 1.0ST Array took an 
extra step to ﬁ  lter out probesets affected by SNPs 
maintained in dbSNP (a database of SNP data 
curated by the National Center for Biotechnology 
Information) when summarizing gene expression 
(Zhang, Duan et al. in press).
Other phenotypic data
Other phenotypic data such as cell growth inhibi-
tion and/or apoptosis after drug treatment and drug 
Figure 1. LCL samples from the International HapMap Project are derived from individuals of European, African and Asian ancestry.17
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metabolizing enzyme activity are being generated 
by various laboratories that use the HapMap cell 
lines as experimental models (Dolan, Newbold 
et al. 2004; Watters, Kraja et al. 2004; Huang, Duan 
et al. 2007; Huang, Duan et al. 2007; Huang, 
Kistner et al. 2007). Published pharmacology-
related phenotypic data on the HapMap samples 
can be accesed at the PharmGKB (Klein, Chang 
et al. 2001) web site (Table 1).
Genetic Determinants of Gene 
Expression Variation
Gene expression as a complex trait or phenotype 
is believed to be a composite reﬂ  ection of multiple 
genetic and non-genetic factors and the genetic 
contribution is consequently often difficult to 
characterize (Stranger, Forrest et al. 2005; Forton 
and Kwiatkowski, 2006; Zhang, Richards et al. 
2007). Understanding patterns of expression 
variation within and among population groups will 
provide important insights into the molecular basis 
of phenotypic diversity and the interpretation of 
patterns of expression variation in disease. The 
International HapMap resource along with asso-
ciation studies has allowed researchers to begin to 
characterize the genetic contribution to gene 
expression variation observed between individuals 
and populations. Impressively, with the availabil-
ity of millions of genotypes already determined for 
cell lines derived from major world populations, 
the HapMap resource has accelerated these gene 
expression studies.
An early study using 35 Centre d’Etude du 
Polymorphisme Humain (CEPH) LCLs including 
some HapMap samples examined ~2500 expressed 
genes for natural variation in gene expression and 
identiﬁ  ed genes whose transcript levels differed 
greatly among unrelated individuals (Cheung, 
Conlin et al. 2003; Cheung, Jen et al. 2003). They 
also found evidence for familial aggregation of 
expression phenotype by comparing variation 
among unrelated individuals, among siblings 
within families and between monozygotic twins. 
These observations suggest that there is a genetic 
contribution to polymorphic variation in the level 
of gene expression. In contrast, using 60 unrelated 
CEU samples from the HapMap, Stranger et al. 
scanned 630 genes (374 expressed) for association 
of SNPs with inter-individual expression variation 
in LCLs. The signal proximal (cis-) to the genes 
of interest was found to be more abundant and more 
stable than those distal and (trans-) across statistical 
methodologies (Stranger, Forrest et al. 2005). 
Impressively, by regional association with only the 
HapMap SNP markers that had strong linkage 
evidence from a previous study (Morley, Molony 
et al. 2004), Cheung et al. were able to conﬁ  rm the 
linkage results and narrow the candidate regulatory 
regions for many expression phenotypes of the 374 
phenotypes they surveyed, while a genome-wide 
association using 770,000 HapMap SNPs yielded 
highly signiﬁ  cant results that point to the same 
locations as the genome scans for about 50% of 
the expression phenotypes. (Cheung, Spielman 
et al. 2005). Recently, Bergen et al. investigated 
the role of cis sequence effects in a group of genes 
commonly studied in cancer research in human 
LCLs. Based on their results and the extensive 
literature, one in four genes exhibits signiﬁ  cant cis 
sequence effects, and for these genes, about 30% 
of gene expression variation is accounted for by 
cis sequence variation (Bergen, Baccarelli et al. 
2007).
Populations differ in prevalence of many com-
plex genetic diseases, such as diabetes and cardio-
vascular disease. However, the genetic basis for 
population differences in clinical outcomes and 
risk of disease is not fully understood (Falkner, 
1990; Burchard, Ziv et al. 2003; Ioannidis, Ntzani 
et al. 2004; Bowen, Stebbing et al. 2006; Calvo 
and Baselga, 2006; Huang, Duan et al. 2007). 
Although contributors to the differences are likely 
to include socioeconomic and/or environmental 
factors, genetic variation, including variation 
affecting gene expression levels, is likely to play 
an important role. Recently, Spielman et al. char-
acterized variation in gene expression in cells from 
individuals belonging to three major population 
groups using the CEU, CHB and JPT samples from 
the HapMap Project. Their results indicate that the 
expression phenotype differs signiﬁ  cantly between 
European-derived and Asian-derived populations 
for 1,097 of 4,197 genes tested. For the expression 
phenotypes with the strongest evidence of cis 
determinants, they found most of the variation is 
due to allele frequency differences at cis-linked 
regulators, suggesting that speciﬁ  c genetic variation 
among populations contributes appreciably to dif-
ferences in gene expression phenotypes (Spielman, 
Bastone et al. 2007). Akey et al. however, sug-
gested that batch effects could be a confounding 
factor when interpreting their results (Akey, Biswas 
et al. 2007). By characterizing patterns of natural 19
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expression variation in 16 individuals from the 
CEU and YRI samples, Storey et al. found 
extensive variation in gene expression levels and 
estimated that approximately 83% of genes are 
differentially expressed among individuals and that 
approximately 17% of genes are differentially 
expressed between the two populations. Further-
more, by decomposing total gene expression 
variation into within- versus among-population 
components, they found that most expression 
variation is due to variation among individuals 
rather than among populations, which parallels 
observations of extant patterns of human genetic 
variation (Storey, Madeoy et al. 2007). In addition 
to conﬁ  rming that common variants account for a 
substantial fraction of the between-population gene 
expression variation, Zhang et al. were able to 
evaluate the contribution of genetic and non-
genetic factors to the observed population differ-
ences using 176 CEU and YRI samples (Zhang, 
Duan et al. in press). The above studies were per-
formed to associate expression phenotype with one 
form of genetic variation, namely, SNPs. In con-
trast, Stranger et al. determined the overall contri-
bution of SNPs and copy number variants (CNVs), 
which belong to another type of common genetic 
variation (i.e. structural variation) to expression 
phenotype by performing association analyses of 
expression levels of 14,925 transcripts with SNPs 
and CNVs in individuals of the four populations 
from HapMap Project. They found that SNPs and 
CNVs captured 83.6% and 17.7% of the total 
detected genetic variation in gene expression, 
respectively, but the signals from the two types of 
variation had little overlap, suggesting interroga-
tion of the genome for both types of variants may 
be an effective way to elucidate the variation in 
complex phenotypes and human diseases (Stranger, 
Forrest et al. 2007).
In addition to many differences between 
populations in transcriptional and translational 
regulation of genes, alternative pre-mRNA splicing 
(AS) is also likely to play an important role in 
regulating gene expression and generating variation 
in mRNA and protein isoforms. It has been 
estimated that between one-third and two-thirds of 
all human genes undergo AS (Sorek, Shamir et al. 
2004) and the disruption of speciﬁ  c AS events has 
been implicated in several human genetic diseases 
(Faustino and Cooper, 2003). Using 22 unrelated 
CEU samples from the HapMap Project, Hull et al. 
demonstrated that six out of 70 exon-skipping 
events they identiﬁ  ed were consistently different 
in splicing pattern between individuals, with a 
highly significant association between splice 
phenotype and neighboring SNPs. Their ﬁ  ndings 
suggest that phenotypic variation in splicing 
patterns is determined by the presence of SNPs 
within ﬂ  anking introns or exons (Hull, Campino 
et al. 2007). Using a comprehensive exon-targeted 
microarray, Kwan et al. examined individual-
speciﬁ  c alternative splicing in 60 unrelated CEU 
samples from the HapMap Project as well as 14 
more CEPH samples. They showed that their 
approach can detect both annotated and novel 
alternatively spliced variants, and that such variation 
among individuals is heritable and genetically 
controlled (Kwan, Benovoy et al. 2007).
Application to Pharmacogenomics
It has been especially difﬁ  cult to dissect genetic 
contribution to common, polygenic diseases as well 
as other clinical phenotypes such as drug response 
in which multiple genetic and environmental factors 
may interact with each other. It is now widely 
accepted that association studies offer greater statis-
tical power over linkage in detecting genetic effects 
underlying these complex traits when the causative 
variant is common in the population (Risch and 
Merikangas, 1996). Besides being used in traditional 
candidate gene approaches, the HapMap resource 
and technology for genome-wide analysis have 
enabled an unbiased approach to detect clinically 
important genetic factors that determine drug effec-
tiveness and side effects between patients (Deloukas 
and Bentley, 2004; Andrawiss, 2005).
Clinical drug responses reﬂ  ect not only proper-
ties intrinsic to the target cell but also host metabolic 
properties, drug-drug interactions, and pharmaco-
kinetics as well as population, gender, age and other 
environmental factors. To evaluate population and 
gender effects and to begin to understand how 
genetic variations contribute to these effects, Huang 
et al. used CEU and YRI trios from the HapMap 
Project to study the population- and gender-speciﬁ  c 
differences for cytotoxicity following treatment 
with carboplatin, cisplatin, daunorubicin, and eto-
poside (Huang, Kistner et al. 2007). They observed 
large inter-individual variance in cytotoxicity as 
represented by IC50 (the drug concentration result-
ing in 50% cell growth inhibition) values for the 
four drugs for both the YRI and CEU samples. They 
also reported drug response differences between 20
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the two populations for two of the drugs they tested 
as well as a signiﬁ  cant difference between females 
and males in the YRI samples for the two platinat-
ing agents. Differences in sensitivity to drugs may 
be explained, to some extent, by differences in gene 
expression between males and females (Zhang, 
Bleibel et al. 2007) or differences between popula-
tions (Zhang, Duan et al. in press). Their results 
show that population and gender may affect risk 
for toxicities associated with certain chemothera-
peutic agents.
One of the major goals of pharmacogenomic 
studies is to identify genetic factors responsible for 
drug effectiveness and side effects among patients. 
When the candidate gene is known, Jones et al. 
demonstrated that the HapMap resource is 
useful for pharmacogenetic discovery by using 
HapMap cell lines and HapMap SNPs to test 
whether a thiopurine methyltransferase (TPMT) 
polymorphism could be identiﬁ  ed as predicting 
TPMT phenotype (Jones, Yang et al. 2007). 
However, challenges remain for deﬁ  nitive gene 
identiﬁ  cation when an unsupervised genome-wide 
approach is employed. Recently, Huang et al. used 
a comprehensive microarray platform to measure 
gene expression levels of the CEU and YRI 
trios from the HapMap Project and performed 
genome-wide association studies with ~380,000 
highly informative HapMap SNPs to successfully 
identify genetic factors that contribute to the 
cytotoxicity of cisplatin and etoposide, which are 
widely prescribed anticancer agents (Huang, Duan 
et al. 2007; Huang, Duan et al. 2007). Utilizing the 
HapMap resource, these authors were able to use 
a genome-wide approach to evaluate associations 
between 1) genotype and drug response, 2) 
genotype and gene expression, and 3) gene 
expression and drug response. The HapMap 
resource has allowed these authors to find 
signiﬁ  cant SNPs associated with both baseline 
gene expression and relative drug response. 
Therefore, genotype, gene expression and sensitivity 
to drug information can be used to identify genetic 
variants responsible for drug response that act 
through expression. Clearly, this level of integration 
of genotype, expression data and other phenotypic 
data could not be possible without a HapMap-like 
resource. In addition, these results will be useful 
to other investigators studying these lines, as the 
drug response data are also publicly available. 
Though further functional validation experiments 
are necessary to conﬁ  rm the ﬁ  ndings, Huang et al. 
showed that utilization of the HapMap resource 
impressively narrowed down the number of 
candidate genetic variants from hundred of 
thousands to just a handful that explain a signiﬁ  cant 
percentage of the human variation in drug 
sensitivity. They hypothesize that each drug has a 
“pharmacogenetic signature” that explains most 
of the variation in drug sensitivity. These 
pharmacogenetic signatures can be integrated into 
clinical studies to determine whether they predict 
for patients at risk for chemotherapeutic-induced 
toxicities or response. The goal is to improve 
responsiveness and reduce adverse events associated 
with these highly toxic drugs.
Advantages and Limitations 
of the HapMap Resource
There are several advantages of the HapMap 
resource. Investigators can utilize extensive geno-
type, gene expression and other phenotypic data 
on the 270 HapMap samples to perform various 
genome-wide scans for studies that do not require 
a priori knowledge, as well as more directed stud-
ies using a candidate gene approach. The HapMap 
samples provide an in vitro model for studies of 
the major world populations, i.e. European, African 
and Asian (including Chinese and Japanese). 
Another advantage to using these samples in phar-
macogenomic studies of drug targets is that a cel-
lular approach avoids the complexities of in vivo 
pharmacokinetic variability. Thus, genetic varia-
tion important in variation in pharmacodynamic 
effects can be teased out. Furthermore, such in vitro 
studies are less expensive and require less time 
than similar studies in human subjects, which 
would also need to consider the potential risks of 
the drugs being tested. Chemotherapy, for example, 
is associated with severe toxicity and therefore 
cannot be given to unaffected family members for 
genetic studies. A number of tools and techniques 
are now available to increase the ease of utilizing 
the HapMap resource, including tools for viewing 
and analyzing haplotype and LD data, identiﬁ  ca-
tion of optimal sets of haplotype tagging SNPs, 
drawing links between associated SNPs and puta-
tive causal alleles or simply viewing LD and hap-
lotypes across a gene or region of interest (Barnes, 
2006).
However, there are some limitations of the 
HapMap resource. LCLs represent just one human 
tissue type, therefore it may not reﬂ  ect tumor 21
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response or sensitivity of target tissue of known 
toxicity. It has been estimated that only ~50–60% 
of human genes are expressed in LCLs (Cheung, 
Conlin et al. 2003). A more comprehensive 
understanding of variation of complex traits or 
phenotypes such as gene expression requires cell 
lines derived from other tissues, because for 
example it has already been known that many 
pharmacology-related genes have distinct tissue-
speciﬁ  c expression patterns (Zhang, Liu et al. 2007). 
Because of the fact that the EBV-transformation 
of LCLs from the CEU and other HapMap samples 
(YRI, CHB, JPT) happened over 20 years apart 
(Dausset, Cann et al. 1990; International HapMap 
Consortium 2003), certain non-genetic factors, 
such as the EBV strains used for transformation or 
the number of freeze/thaw cycles, could lead to 
differences in gene expression between these 
samples, thus the comparative results using these 
samples could be confounded by non-genetic 
factors. An appropriate approach that takes 
consideration of these effects, therefore, is 
recommended for these studies (Akey, Biswas et al. 
2007). Studies suggest EBV transformation may 
affect the expression of some genes and certain 
biological processes in LCLs (Liu, Chen et al. 
2004; Tobollik, Meyer et al. 2006). Therefore, 
interpretation of results using these cell lines may 
be biased by this effect.
Conclusion and Outlook
The HapMap resource has allowed population-
based studies regarding the contribution of genetic 
factors to variation in complex traits or phenotypes 
such as gene expression, drug response and sus-
ceptibility/cause of common disease in humans, as 
well as other studies in population genetics and 
evolution. For example, recent progess using the 
HapMap resource has begun to illustrate the con-
tribution of common genetic variants to natural 
variation in gene expression within and among 
major world populations. Studies like these are 
providing new insights into the human genome and 
cell biology, thus changing our view of ourselves. 
The HapMap resource is also facilitating pharma-
cogenomic studies to identify genetic variants 
important in gene expression and sensitivity to 
chemotherapy, thus lending the promise of person-
alized medicine in the future.
Clearly, recent studies using the HapMap 
resource have shown its applicability to detect 
common genetic variants important for variation in 
complex traits or phenotypes such as development 
of common diseases (Ait Yahya-Graison, Aubert 
et al. 2007; Barnes, Grant et al. 2007; Kakiuchi, 
Ishiwata et al. 2007; Salonen, Uimari et al. 2007) 
and the two areas of focus in this review: gene 
expression and drug response. However, the 
HapMap resource will become an even more 
powerful tool if it is integrated with other resources 
such as a full catalogue of functional variants, 
databases of genetic elements (e.g. transcript factor 
binding sites, exonic splicing enhancers and 
microsatellites) and databases of functional 
annotations (e.g. gene ontology and known pathways). 
Since the current HapMap genotypic data is 
comprised of ~4 million common SNPs, it remains 
a challenging task to identify rare or untyped SNPs 
using this resource. Therefore, deep resequencing 
or a denser genotyping microarray may be needed 
to uncover more SNPs in the HapMap samples. One 
effort to resequence the HapMap samples is the 
coordination of the HapMap Project and the 
ENCODE (ENCyclopedia Of DNA Elements) 
Project (ENCODE Project Consortium 2004). The 
latter aims to identify all functional elements in the 
human genome and involves resequencing of 
10 500Kb HapMap-ENCODE regions in 48 
unrelated individuals (16 YRI, 16 CEU, 8 CHB and 
8 JPT) using a PCR-based method. Approximately 
20,000 SNPs were identified in the HapMap-
ENCODE regions. Some of these were already 
represented in dbSNP, while others were discovered 
during the resequencing. Genotype data were 
obtained from these SNPs of all 270 HapMap 
samples. The candidate gene approach, which 
requires a priori knowledge of certain biological 
processes or pathways, can be complemented by 
targeted deep resequencing to discover rarer 
variants, while the whole-genome approach using 
the HapMap resource can be used to identify new 
targets of interest in an unbiased way. Finally, as 
more and more genotypic and phenotypic data on 
the HapMap samples are made publicly available 
by researchers worldwide, sharing and cross-
referencing these datasets will be difﬁ  cult. Therefore, 
it is evident that appropriate bioinformatics 
techniques and statistical methods need to be 
developed so that researchers have the opportunity 
to comprehensively incorporate the complex 
networks of various relationships (e.g. gene-
environment, gene-drug, gene-gender, gene-age, 
cis- or trans- regulators) that affect complex traits.22
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